Uterine Cancer Study Act of 2025
Uterine Cancer Study Act of 2025 directs the Secretary of Health and Human Services, in coordination with the FDA Commissioner and the NIH Director, to conduct a focused study on the relationship between chemical hair straighteners and uterine cancer, with particular attention to higher incidence among women of color. The bill requires reviewing existing research, considering impacts across all racial and ethnic groups, and disaggregating findings by product type (dyes/ coloring, bleach, highlights, or perms). It also asks the study to assess whether the FDA should impose additional testing requirements on hair straightening product manufacturers. The Secretary must outline a research methodology within 45 days, begin the study within 180 days, and complete a final report within 2 years. In short, the bill creates a time-bound, government-commissioned study to evaluate potential links between hair straighteners and uterine cancer and to consider regulatory actions if warranted, emphasizing disparities affecting women of color.
Key Points
- 1Purpose: Directs a formal study on the relationship between chemical hair straighteners and uterine cancer, focusing on women of color.
- 2Agencies: Requires cooperation between the Secretary of Health and Human Services, the FDA Commissioner, and the NIH Director.
- 3Data disaggregation: Results must be broken out by product characteristics, including whether the product contains dyes/coloring, bleach, highlights, or perms.
- 4Regulatory consideration: The study will determine whether additional FDA testing requirements should be imposed on manufacturers to ensure safety.
- 5Timelines:
- 6- Methodology description due within 45 days of enactment.
- 7- Study commencement within 180 days.
- 8- Final report due within 2 years of enactment.